Brown Brothers Harriman & Co. Sells 1,071 Shares of Solventum Co. (NYSE:SOLV)

Brown Brothers Harriman & Co. trimmed its stake in Solventum Co. (NYSE:SOLV) by 20.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,222 shares of the company’s stock after selling 1,071 shares during the period. Brown Brothers Harriman & Co.’s holdings in Solventum were worth $279,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Modus Advisors LLC purchased a new position in Solventum during the fourth quarter worth $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum during the 4th quarter worth about $26,000. Crews Bank & Trust purchased a new position in shares of Solventum during the 4th quarter worth about $32,000. True Wealth Design LLC grew its holdings in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after purchasing an additional 471 shares during the last quarter. Finally, Synergy Asset Management LLC purchased a new stake in Solventum in the 4th quarter worth about $35,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company lifted their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Mizuho upped their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Finally, The Goldman Sachs Group lifted their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Stock Up 1.7 %

Shares of Solventum stock opened at $76.02 on Tuesday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a market cap of $13.15 billion and a price-to-earnings ratio of 27.64. The firm’s 50-day moving average is $75.56 and its two-hundred day moving average is $71.92.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.